IceCure Medical (ICCM) vs Trinity Biotech (TRIB)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
IceCure Medical is the larger company by market cap ($5.2 million vs $4.9 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ICCM | TRIB |
|---|---|---|
| Share price | $1.13 | $6.04 |
| Market cap | $5.24M | $4.91M |
| 1-day change | -1.74% | -10.91% |
| EPS (TTM) | $-6.84 | $-60.00 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $30.30 | $52.50 |
| 52-week low | $1.05 | $5.01 |
| Distance from 52-week high | -96.27% | -88.50% |
| Analyst consensus | none | — |
| Avg. price target upside | +1906.19% | — |
| Average volume | 136.91K | 21.66K |
| Shares outstanding | 4.64M | 813.13K |
| Employees | 67 | 287 |
| Sector | Healthcare | Healthcare |
| Industry | Medical Devices | Medical Devices |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About IceCure Medical
ICCM stock →IceCure Medical Ltd, a commercial-stage medical device company, engages in the research, development, and marketing of cryoablation systems, disposables, and technologies for treating tumors in the United States, Japan, India, China, Israel, and internationally. The company offers the ProSense system, a single probe cryoablation system for the treatment of malignant breast tumors, as well as its associated disposables, including CryoProbes needles, and guiding needles/introducers; and IceSense3 system for ablation indications in urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology.
Healthcare · Medical Devices · 67 employees
About Trinity Biotech
TRIB stock →Trinity Biotech plc, together with its subsidiaries, develops, acquires, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the Americas, Asia, Africa, and Europe. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detects infectious diseases; sexually transmitted diseases, such as syphilis and herpes; SARS-CoV-2; and epstein barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, varicella and other viral pathogens, as well as products for the in-vitro diagnostic measurement of haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a risk of developing diabetes.
Healthcare · Medical Devices · 287 employees
ICCM vs TRIB FAQ
Which is bigger, IceCure Medical or Trinity Biotech?
IceCure Medical (ICCM) is larger, with a market capitalization of $5.24M compared with $4.91M for Trinity Biotech (TRIB).
Are IceCure Medical and Trinity Biotech in the same industry?
Yes. Both are classified in the Medical Devices industry within the Healthcare sector.